Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary L Johnson

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2Marwah Karim, Manjari Mishra, Chieh-Wen Lo, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
Cancer Discovery|January 22, 2017
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb ComplexJon S Zawistowski, Samantha M Bevill, Daniel R Goulet, et al.
Neuro-Oncology|April 6, 2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, et al.
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinomeMichael P East, Robert W Sprung, Denis O Okumu, et al.
Journal of Pharmaceutical Innovation|June 9, 2022
FDA Approaches in Monitoring Drug Quality, Forces Impacting the Drug Quality, and Recent Alternative Strategies to Assess Quality in the US Drug SupplyPhilip J Almeter, James T Isaacs, Aaron N Hunter, et al.
Cell|April 17, 2012
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancerJames S Duncan, Martin C Whittle, Kazuhiro Nakamura, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2Marwah Karim, Manjari Mishra, Chieh-Wen Lo, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
Cancer Discovery|January 22, 2017
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb ComplexJon S Zawistowski, Samantha M Bevill, Daniel R Goulet, et al.
Neuro-Oncology|April 6, 2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, et al.
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Biorxiv : the Preprint Server for Biology|October 28, 2024
Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinomeMichael P East, Robert W Sprung, Denis O Okumu, et al.
Journal of Pharmaceutical Innovation|June 9, 2022
FDA Approaches in Monitoring Drug Quality, Forces Impacting the Drug Quality, and Recent Alternative Strategies to Assess Quality in the US Drug SupplyPhilip J Almeter, James T Isaacs, Aaron N Hunter, et al.
Cell|April 17, 2012
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancerJames S Duncan, Martin C Whittle, Kazuhiro Nakamura, et al.
Pageof 18